Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 167 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Etanercept Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

NCT00285233
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Allogeneic islets of Langerhans transplant
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL

NCT00048373
View directory record Official record
Conditions
Histiocytosis, Langerhans-Cell
Interventions
Etanercept
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Early Phase 1 Interventional

Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

NCT05281614
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Etanercept, Vedolizumab
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Etanercept in Dermatomyositis

NCT00112385
View directory record Official record
Conditions
Dermatomyositis
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Treatments Against RA and Effect on FDG-PET/CT

NCT02374021
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 17, 2026, 4:04 AM EDT
Terminated Phase 2Phase 3 Interventional

Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

NCT00035958
View directory record Official record
Conditions
Dermatomyositis
Interventions
Prednisone, Methotrexate, Etanercept
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

NCT02373813
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
etanercept pre-filled syringe subcutaneous injection, Oral methotrexate, Placebo for etanercept subcutaneous injection, Placebo for methotrexate, Folic acid (non-investigational product)
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
74
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 17, 2026, 4:04 AM EDT
Terminated Not applicable Interventional Results available

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

NCT00477191
View directory record Official record
Conditions
Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
Interventions
Etanercept
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

NCT02134210
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept, CHS-0214
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

NCT00091741
View directory record Official record
Conditions
HIV Infection
Interventions
Etanercept (Enbrel)
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

NCT01331837
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
3,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
143
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 17, 2026, 4:04 AM EDT
Completed No phase listed Observational

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

NCT04772248
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, TNF Inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
105,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Placebo, secukinumab (AIN457), etanercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 17, 2026, 4:04 AM EDT
Not listed Phase 4 Interventional

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

NCT01793519
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Infliximab, Adalimumab, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 17, 2026, 4:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Treatment of Hidradenitis Suppurativa Using Etanercept

NCT00949546
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
etanercept
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 17, 2026, 4:04 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

NCT01522742
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00217386
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, etanercept
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
4
States / cities
Bellingham, Washington • Port Angeles, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Oct 17, 2026, 4:04 AM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 4:04 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus

NCT00797784
View directory record Official record
Conditions
Discoid Lupus Erythematosus (DLE)
Interventions
etanercept(Enbrel®)
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Oct 17, 2026, 4:04 AM EDT
Withdrawn No phase listed Observational

Evaluation of Vitamin D Levels in Psoriasis Patients

NCT01903317
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 3 Interventional

Islet Transplantation in Type 1 Diabetes

NCT00434811
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Blocking Tumor Necrosis Factor in Ankylosing Spondylitis

NCT00000433
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Anti-Tumor Necrosis Factor
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Oct 17, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis

NCT02274792
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 125 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
33
States / cities
Mobile, Alabama • Bakersfield, California • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 17, 2026, 4:04 AM EDT